Fatigue News and Research

RSS

SPS receives $2.2M NHLBI grant to commercialize steerable cardiac mapping, ablation catheter technology

Strategic Polymer Sciences, Inc. (SPS), an innovator in advanced medical devices based on its proprietary electroactive polymer (EAP) technology, today announced it has received a $2.2 million grant from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The SPS grant is one of only ten awarded nationwide by the NIH under a Recovery Act Limited Competition called The Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program.

23 Jun 2010

AIDS specialist leaves Calif. practice, citing rising costs

A long-time San Francisco AIDS specialist is closing his clinic and moving to Manhattan because of frustration with the insurance industry and the rising cost of practicing medicine, the San Francisco Chronicle reports. "The bottom line is, you cannot make a living practicing medicine unless you work at least 50 to 60 hours a week," said Dr. Marcus Conant, one of the first AIDS doctors in the area. "I'm not the only doctor who's getting to the point where it's not worth it."

23 Jun 2010

Elevation of Smurf1 may play a role in molecular basis of PAH: Study

Pulmonary arterial hypertension (PAH) is a progressive disease, marked by shortness of breath and fatigue which can be fatal if untreated. Increased pressure in the pulmonary artery and its branches is associated with dysfunctional growth control of endothelial and smooth muscle cells leading to excessive thickening of the blood vessel wall, obliteration of the lumen and right heart failure.

22 Jun 2010

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

BioSante Pharmaceuticals, Inc. commented today that the recommendation on June 18, 2010 by the FDA Advisory Committee regarding the safety and efficacy of flibanserin (Boehringer-Ingelheim) will have no impact on its own ongoing development program or approval pathway for LibiGel (testosterone gel), for the treatment of hypoactive sexual desire disorder (HSDD).

22 Jun 2010

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.

22 Jun 2010

Lightning Safety Awareness Campaign reduces death and injury from lightning strikes in the U.S.

This year marks the 10th Lightning Safety Awareness Campaign, June 20-26. Spearheaded by the National Weather Service, the campaign has reduced death and injury from lightning strikes in the U.S., with average annual deaths dropping from 72 to 40 in the last decade.

19 Jun 2010

CFIDS Association applauds AABB for responding to questions about safety of general blood supply

The CFIDS Association of America commends the AABB (formerly the American Association of Blood Banking) for its actions to protect the safety of the nation's blood supply by recommending that blood collectors actively discourage potential donors who have been diagnosed by a physician with chronic fatigue syndrome (CFS, also known as chronic fatigue and immune dysfunction syndrome, or CFIDS) from donating blood through the use of donor information materials made available at the donation site.

19 Jun 2010

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism on Saturday, June 19.

18 Jun 2010

If you suffer from sleep apnea, consult with your dentist: PDA

Sleep apnea, a serious and potentially life-threatening disorder if left untreated, affects approximately 18 million Americans. During sleep apnea episodes, a person stops breathing for at least 10 seconds. Depending on the severity of the disorder, a person can have between 10 and 60 episodes a night. Sleep apnea treatment often involves a team of healthcare providers, including dentists, general physicians, surgeons and sleep specialists.

18 Jun 2010

FDA approves new indication for Tasigna in treatment of rare blood cancer

The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.

18 Jun 2010

FDA approves Jevtana to treat men with prostate cancer

The U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. Jevtana is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after treatment with docetaxel, a commonly used drug for advanced prostate cancer.

18 Jun 2010

$FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer$

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana® (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen.

18 Jun 2010

St. Jude Medical commences enrollment in LAPTOP-HF study

St. Jude Medical, Inc., a global medical device company, today announced the first enrollment in its LAPTOP-HF (Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy) study. The goal of the LAPTOP-HF study is to demonstrate that the new investigational left atrial pressure (LAP) management system safely and effectively improves outcomes in patients with heart failure (HF).

17 Jun 2010

Scientists identify symptoms associated with late-onset hypogonadism

Scientists have for the first time identified the symptoms associated with what has been termed late-onset hypogonadism or 'male menopause' caused by a reduction in testosterone production in ageing men.

17 Jun 2010

Renewed threat of Medicare pay cuts leaves doctors with 'sense of fatigue'

Doctors across the country find themselves - once again - putting their Medicare claims on hold while they wait for Congress to take action.

17 Jun 2010

First Edition: June 16, 2010

Today's health policy headlines focus on the latest Senate developments regarding the Medicare 'doc fix' as well as continuing health reform implementation news.

16 Jun 2010

Vitamin D may help reduce incidence, severity of viral respiratory tract infections: Study

Vitamin D may help reduce the incidence and severity of viral respiratory tract infections including influenza, according to a new study conducted by investigators at Greenwich Hospital and Yale University School of Medicine.

16 Jun 2010

Hemispherx announces exclusive revenue sharing agreement with GP Pharm

Hemispherx Biopharma, Inc., announced that the Company executed an exclusive revenue sharing Sales, Marketing, Distribution and Supply Agreement for Argentina with GP Pharm Latinoamerica, an affiliate company of Spanish GP Pharm SA.

16 Jun 2010

FDA cautions on infant overdose risk with liquid Vitamin D

The Food and Drug Administration today alerted parents and caregivers that some liquid Vitamin D supplement products are sold with droppers that could allow excessive dosing of Vitamin D to infants.

16 Jun 2010

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Biogen Idec today announced enrollment of the first patient in a multicenter Phase II clinical trial designed to evaluate its investigational oral therapy BG-12 (dimethyl fumarate) in combination with commonly used first-line treatments in patients with relapsing-remitting multiple sclerosis (RRMS).

15 Jun 2010

Fatigue News and Research

SPS receives $2.2M NHLBI grant to commercialize steerable cardiac mapping, ablation catheter technology

AIDS specialist leaves Calif. practice, citing rising costs

Elevation of Smurf1 may play a role in molecular basis of PAH: Study

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Lightning Safety Awareness Campaign reduces death and injury from lightning strikes in the U.S.

CFIDS Association applauds AABB for responding to questions about safety of general blood supply

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

If you suffer from sleep apnea, consult with your dentist: PDA

FDA approves new indication for Tasigna in treatment of rare blood cancer

FDA approves Jevtana to treat men with prostate cancer

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

St. Jude Medical commences enrollment in LAPTOP-HF study

Scientists identify symptoms associated with late-onset hypogonadism

Renewed threat of Medicare pay cuts leaves doctors with 'sense of fatigue'

First Edition: June 16, 2010

Vitamin D may help reduce incidence, severity of viral respiratory tract infections: Study

Hemispherx announces exclusive revenue sharing agreement with GP Pharm

FDA cautions on infant overdose risk with liquid Vitamin D

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News